Literature DB >> 9829747

Cytotoxicity and DNA fragmentation associated with sequential gemcitabine and 5-fluoro-2'-deoxyuridine in HT-29 colon cancer cells.

Q Ren1, V Kao, J L Grem.   

Abstract

The combined cytotoxic effects of the antimetabolites gemcitabine (dFdCyd) and 5-fluoro-2'-deoxyuridine (FdUrd) were studied. Cytotoxicity, biochemical perturbations, and DNA damage seen with dFdCyd and FdUrd alone and in combination were evaluated in HT-29 human colon cancer cells. A 4-h exposure to dFdCyd followed by FdUrd for 24 h produced more than additive cytotoxicity and marked S-phase accumulation. Cells progressed through the cell cycle, however, after a 22-h drug-free interval. [3H]dFdCyd was rapidly metabolized to the 5'-triphosphate and incorporated into DNA. [3H]FdUrd was anabolized exclusively to FdUrd monophosphate, and preexposure to dFdCyd did not affect FdUrd monophosphate formation. Thymidylate synthase catalytic activity was inhibited by 48% after a 4-h exposure to 10 nM FdUrd and by 80% after exposure to the combination. Sequential 4-h exposures to 15 nM dFdCyd and 10 nM FdUrd led to greater depletion of dTTP pools (29% of control) than with either drug alone. Greater effects on nascent DNA integrity were seen with sequential dFdCyd followed by FdUrd. Although parental DNA damage was not evident immediately after exposure to 15 nM dFdCyd for 4 h followed by 10 nM FdUrd for 24 h, high molecular mass DNA fragmentation was evident 72-96 h after drug removal. Sequential dFdCyd/FdUrd was associated with prominent disturbance of the cell cycle, dTTP pool depletion, dATP/dTTP imbalance, and nascent DNA damage. Induction of double-strand parental DNA damage and cell death was delayed, consistent with postmitotic apoptosis.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9829747

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  15 in total

Review 1.  Preclinical Rationale for the Phase III Trials in Metastatic Pancreatic Cancer: Is Wishful Thinking Clouding Successful Drug Development for Pancreatic Cancer?

Authors:  Ramya Thota; Anirban Maitra; Jordan D Berlin
Journal:  Pancreas       Date:  2017-02       Impact factor: 3.327

2.  Modified GTX as Second-Line Chemotherapy in Advanced Pancreatic Cancer.

Authors:  Haifa Dbouk; Hana Ajouz; Ali Shamseddine; Deborah Mukherji; Eileen M O'Reilly; Ali Haydar; David Kelsen; Mohamed Naghy; Mohamed Eloubeidi; Fadi Geara; Leonard Saltz; Ghassan K Abou-Alfa
Journal:  Gastrointest Cancer Res       Date:  2013-07

3.  Impact of CYP2C19 polymorphism on the pharmacokinetics of nelfinavir in patients with pancreatic cancer.

Authors:  Krishna Kattel; Ruby Evande; Chalet Tan; Goutam Mondal; Jean L Grem; Ram I Mahato
Journal:  Br J Clin Pharmacol       Date:  2015-06-11       Impact factor: 4.335

4.  Comparison of the efficacy and the toxicity between gemcitabine with capecitabine (GC) and gemcitabine with erlotinib (GE) in unresectable pancreatic cancer.

Authors:  Eun Kyoung Jeon; Hye-Sung Won; Yoon-Ho Ko; In Seok Lee; Tae Ho Hong; Young Kyoung You; Myung Ah Lee
Journal:  J Cancer Res Clin Oncol       Date:  2012-05-22       Impact factor: 4.553

5.  Leucovorin, 5-fluorouracil, and gemcitabine: a phase I study.

Authors:  E Poplin; J Roberts; M Tombs; S Grant; E Rubin
Journal:  Invest New Drugs       Date:  1999       Impact factor: 3.850

6.  VEGF remains an interesting target in advanced pancreas cancer (APCA): results of a multi-institutional phase II study of bevacizumab, gemcitabine, and infusional 5-fluorouracil in patients with APCA.

Authors:  L K Martin; X Li; B Kleiber; E C Ellison; M Bloomston; M Zalupski; T S Bekaii-Saab
Journal:  Ann Oncol       Date:  2012-07-05       Impact factor: 32.976

Review 7.  5-Fluorouracil: forty-plus and still ticking. A review of its preclinical and clinical development.

Authors:  J L Grem
Journal:  Invest New Drugs       Date:  2000-11       Impact factor: 3.850

8.  Modified GTX as second-line therapy for advanced pancreatic adenocarcinoma.

Authors:  Hana Ajouz; Deborah Mukherji; Ali Haydar; Ahmad Sharif Yakan; Ahmad Saleh; Elias Elias; Sally Temraz; Walid Faraj; Mohammad Khalife; Ali Shamseddine
Journal:  J Gastrointest Cancer       Date:  2014-03

9.  Algorithmic modeling quantifies the complementary contribution of metabolic inhibitions to gemcitabine efficacy.

Authors:  Ozan Kahramanoğullari; Gianluca Fantaccini; Paola Lecca; Daniele Morpurgo; Corrado Priami
Journal:  PLoS One       Date:  2012-12-11       Impact factor: 3.240

10.  Capecitabine: an evidence-based review of its effectiveness in the treatment of carcinoma of the pancreas.

Authors:  David B Smith; John P Neoptolemos
Journal:  Core Evid       Date:  2007-11-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.